News

Sarepta Stock Drops After Downgrade and FDA Probe. The Crisis Explained.
Sarepta Therapeutics stock was sliding again on Monday, as investors struggled to make sense of further bad news concerning ...
Sarepta rises 2%; Barclays downgrades to underweight on liquidity and Elevidys concerns
Sarepta Therapeutics (SRPT) shares dropped sharply on Monday following news that the FDA is investigating a patient death potentially connected to its gene therapy, Elevidys.
Sarepta Therapeutics: Beaten Down, But Not Out
Sarepta Therapeutics now trades at book value with strong cash and cost-cutting plans, while ELEVIDYS may regain broader use.
Investor's Business Daily on MSN3d
The Hits Keep Coming For Sarepta. Why Its Latest Setback Creates A 'Dangerous Precedent.'
Sarepta stock plunged again Thursday on a report the FDA will require additional clinical testing to validate the safety ...
Sarepta stock faces multiple downgrades and questions of solvency amid Elevidys pause
For Sarepta, the hits keep coming, with several downgrades in the past week after it was forced to temporarily take its ...
Investor's Business Daily on MSN6d
Sarepta's 'Unprecedented Times' Continue As Company Rebukes The FDA
Sarepta stock took another dive Monday after the biotech company refused the FDA's request to voluntarily stop all shipments ...